Literature DB >> 7479728

Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.

L M Babé1, J Rosé, C S Craik.   

Abstract

Production of infectious human immunodeficiency virus (HIV) requires proper polyprotein processing by the dimeric viral protease. The trans-dominant inhibitory activity of a defective protease monomer with the active site Asp-25 changed to Asn was measured by transient transfection. A proviral plasmid that included the drug-selectable Escherichia coli gpt gene was used to deliver the wild-type (wt) or mutant proteases to cultured cells. Coexpression of the wt proviral DNA (HIV-gpt) with increasing amounts of the mutant proviral DNA (HIV-gpt D25N) results in a concomitant decrease in proteolytic activity monitored by in vivo viral polyprotein processing. The viral particles resulting from inactivation of the protease were mostly immature, consisting predominantly of unprocessed p55gag and p160gag-pol polyproteins. In the presence of HIV-1 gp160 env, the number of secreted noninfectious particles correlated with the presence of increasing amounts of the defective protease. Greater than 97% reduction in infectivity was observed at a 1:6 ratio of wt to defective protease DNA. This provides an estimate of the level of inhibition required for effectively preventing virion processing. Stable expression of the defective protease in monkey cells reduced the yield of infectious particles from these cells by 90% upon transfection with the wt proviral DNA. These results show that defective subunits of the viral protease exert a trans-dominant inhibitory effect resulting from the formation of catalytically compromised heterodimers in vivo, ultimately yielding noninfectious viral particles.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479728      PMCID: PMC40737          DOI: 10.1073/pnas.92.22.10069

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1.

Authors:  M A Navia; P M Fitzgerald; B M McKeever; C T Leu; J C Heimbach; W K Herber; I S Sigal; P L Darke; J P Springer
Journal:  Nature       Date:  1989-02-16       Impact factor: 49.962

2.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.

Authors:  A Wlodawer; M Miller; M Jaskólski; B K Sathyanarayana; E Baldwin; I T Weber; L M Selk; L Clawson; J Schneider; S B Kent
Journal:  Science       Date:  1989-08-11       Impact factor: 47.728

Review 3.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

4.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

Review 5.  Assembly of animal viruses at cellular membranes.

Authors:  E B Stephens; R W Compans
Journal:  Annu Rev Microbiol       Date:  1988       Impact factor: 15.500

6.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

Authors:  D Trono; M B Feinberg; D Baltimore
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

7.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

Authors:  K A Page; N R Landau; D R Littman
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.

Authors:  C Debouck; J G Gorniak; J E Strickler; T D Meek; B W Metcalf; M Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.

Authors:  J R Rosé; L M Babé; C S Craik
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more
  19 in total

1.  Genetic selection for dissociative inhibitors of designated protein-protein interactions.

Authors:  S H Park; R T Raines
Journal:  Nat Biotechnol       Date:  2000-08       Impact factor: 54.908

2.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  HIV protease-activated molecular switches based on beta-glucuronidase and alkaline phosphatase.

Authors:  Taryn L O'Loughlin; Ichiro Matsumura
Journal:  Comb Chem High Throughput Screen       Date:  2006-05       Impact factor: 1.339

4.  Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.

Authors:  Jane M Sayer; Fengling Liu; Rieko Ishima; Irene T Weber; John M Louis
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

5.  Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation.

Authors:  F McPhee; A C Good; I D Kuntz; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

Authors:  M Shehu-Xhilaga; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication.

Authors:  M Hung; P Patel; S Davis; S R Green
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.

Authors:  Michael E Abram; Michael A Parniak
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Sprouty2 regulates PI(4,5)P2/Ca2+ signaling and HIV-1 Gag release.

Authors:  Lorna S Ehrlich; Gisselle N Medina; Carol A Carter
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

10.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Authors:  Hironori Hayashi; Nobutoki Takamune; Takashi Nirasawa; Manabu Aoki; Yoshihiko Morishita; Debananda Das; Yasuhiro Koh; Arun K Ghosh; Shogo Misumi; Hiroaki Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.